

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/E3C731D82464EN.html>

Date: September 2022

Pages: 37

Price: US\$ 2,000.00 (Single User License)

ID: E3C731D82464EN

Abstracts

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2022, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline landscape.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System

And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Discovery and Unknown stages are 4, 1, 1, 1 and 1 respectively.

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved
in Therapeutics Development

Aronora Inc

Bayer AG

BioAegis Therapeutics Inc

Daiichi Sankyo Co Ltd

Eagle Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

KidneyCure Ltd

VESSL Therapeutics Ltd

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued
Products

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product
Development Milestones

Featured News & Press Releases

Jul 29, 2022: Ionis reports positive Phase IIb data of fesomersen for thrombosis

Jul 28, 2022: Phase 2b studies of investigational selective coagulation modulator
osocimab in patients with advanced renal disease completed

Jul 19, 2021: Aronora reports positive topline data from phase 2 study of AB023 in
hemodialysis patients

Dec 02, 2020: Aronora announces clinical data to be presented at the 62nd American

Society of Hematology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Aronora Inc, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bayer AG, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Daiichi Sankyo Co Ltd, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Eagle Pharmaceuticals Inc, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Ionis Pharmaceuticals Inc, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by KidneyCure Ltd, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, 2022

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/E3C731D82464EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E3C731D82464EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

